Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Gansu beckons as destination of beauty and progressXi Focus: Xi Chairs Milestone Summit, Hails New Era of ChinaXi Holds Talks with Tajik PresidentSpring flowers enchant people across ChinaSpring flowers enchant people across ChinaXi Congratulates and Encourages Teachers and Students of Macau University of Science and TechnologyTourists view cherry blossoms at Yuyuantan Park in BeijingPeng Liyuan, African First Ladies Launch Health Campaign for Orphans in AfricaXi Sends Congratulations to Micronesia's New PresidentXi Sends Congratulatory Letter to Forum on Development of Tibet
2.9143s , 6497.1640625 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Gazetteer news portal